ZA98256B - Tachykinin antagonists - Google Patents

Tachykinin antagonists

Info

Publication number
ZA98256B
ZA98256B ZA98256A ZA98256A ZA98256B ZA 98256 B ZA98256 B ZA 98256B ZA 98256 A ZA98256 A ZA 98256A ZA 98256 A ZA98256 A ZA 98256A ZA 98256 B ZA98256 B ZA 98256B
Authority
ZA
South Africa
Prior art keywords
tachykinin antagonists
tachykinin
antagonists
Prior art date
Application number
ZA98256A
Other languages
English (en)
Inventor
Christopher Simon John Walpole
Mahavir Prashad
Denis Har
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA98256B publication Critical patent/ZA98256B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA98256A 1997-01-14 1998-01-13 Tachykinin antagonists ZA98256B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9700597.9A GB9700597D0 (en) 1997-01-14 1997-01-14 Organic compounds

Publications (1)

Publication Number Publication Date
ZA98256B true ZA98256B (en) 1998-07-14

Family

ID=10805904

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA98256A ZA98256B (en) 1997-01-14 1998-01-13 Tachykinin antagonists

Country Status (14)

Country Link
US (1) US6107293A (ja)
EP (1) EP0964867B1 (ja)
JP (2) JP4306804B2 (ja)
AR (1) AR011521A1 (ja)
AT (1) ATE290546T1 (ja)
AU (1) AU5764298A (ja)
CA (1) CA2278057C (ja)
CO (1) CO4950614A1 (ja)
DE (1) DE69732715T2 (ja)
ES (1) ES2239368T3 (ja)
GB (1) GB9700597D0 (ja)
PT (1) PT964867E (ja)
WO (1) WO1998031704A2 (ja)
ZA (1) ZA98256B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005231A1 (en) * 1998-07-20 2000-02-03 Pfizer Limited Fkbp inhibitors

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426331B1 (en) 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
EP1930021A3 (en) 1999-02-18 2008-06-18 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
AU2000249828A1 (en) * 2000-05-03 2001-11-12 Taisho Pharmaceutical Co. Ltd. Stat4 and stat6 binding dipeptide derivatives
US6884782B2 (en) 2000-11-08 2005-04-26 Amgen Inc. STAT modulators
US20070219214A1 (en) * 2006-02-01 2007-09-20 Solvay Pharmaceuticals Gmbh Dual NK2/NK3-antagonists, pharmaceutical compositions comprising them, and processes for their preparation
CN101600724B (zh) 2006-10-16 2013-03-13 狮王株式会社 Nk1受体拮抗剂组合物
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
CA3091944A1 (en) 2018-02-26 2019-08-29 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210669A (en) * 1983-12-27 1988-05-30 Syntex Inc Benzoxazin-4-one derivatives and pharmaceutical compositions
GB8929070D0 (en) * 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
FR2719312B1 (fr) * 1994-04-28 1996-06-14 Adir Nouveau pseudopeptides dérivés de neurokinines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005231A1 (en) * 1998-07-20 2000-02-03 Pfizer Limited Fkbp inhibitors

Also Published As

Publication number Publication date
EP0964867B1 (en) 2005-03-09
GB9700597D0 (en) 1997-03-05
CO4950614A1 (es) 2000-09-01
US6107293A (en) 2000-08-22
JP3817256B2 (ja) 2006-09-06
ES2239368T3 (es) 2005-09-16
DE69732715T2 (de) 2006-04-13
DE69732715D1 (de) 2005-04-14
JP2006089499A (ja) 2006-04-06
WO1998031704A2 (en) 1998-07-23
AU5764298A (en) 1998-08-07
CA2278057A1 (en) 1998-07-23
ATE290546T1 (de) 2005-03-15
JP2000516257A (ja) 2000-12-05
JP4306804B2 (ja) 2009-08-05
CA2278057C (en) 2004-05-04
WO1998031704A3 (en) 1998-09-11
PT964867E (pt) 2005-07-29
AR011521A1 (es) 2000-08-30
EP0964867A2 (en) 1999-12-22

Similar Documents

Publication Publication Date Title
ZA983062B (en) Gnrh antagonists
AU1842995A (en) N-acylpiperidine tachykinin antagonists
HU9501249D0 (en) Non-peptidyl tachykinin receptor antagonists
AU4343796A (en) Tachykinin antagonists
EP0819005A4 (en) 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS
EP1007026A4 (en) INTEGRIN ANTAGONISTS
HUT74808A (en) Gnrh antagonists
EP0934305A4 (en) INTEGRINE ANTAGONISTS
EP0946164A4 (en) INTEGRIN ANTAGONISTS
HU9601176D0 (en) Adhesion-receptor antagonists
IL134993A0 (en) New npy antagonists
NZ324712A (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
HK1031726A1 (en) Thrombin receptor antagonists
IL134175A0 (en) Endothelin antagonists
IL142045A0 (en) Naphthalenecarboxamides as tachykinin receptor antagonists
IL134301A0 (en) 2-acylaminopropanamines as tachykinin receptor antagonists
HU9503191D0 (en) Adhesion-receptor antagonists
ZA98256B (en) Tachykinin antagonists
IL134155A0 (en) 2-acylaminopropanamines as tachykinin receptor antagonists
ZA985209B (en) Endothelin antagonists
ZA9510618B (en) Tachykinin antagonists
ZA987787B (en) LFA-1 antagonists
DK0964867T3 (da) Tachykininantagonister
GB9703015D0 (en) Alpha v B3 antagonists
GB9702922D0 (en) Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists